Abstract

Breast epithelial stem cells are thought to be the primary targets in the etiology of breast cancer. Since breast cancers are predominantly steroid receptor-positive, we tested the hypothesis that normal human breast epithelial stem cells include a steroid receptor-positive population. Based on studies in hematopoietic and other tissues, we isolated a breast epithelial side population (SP) reported to be enriched in stem cells. Fluorescence-activated cell sorting analysis indicates that 5% of breast epithelial cells are SP in nature. Seventy per cent of SP cells lack markers of myoepithelial (CALLA) and luminal cells (MUC1), suggesting that they are undifferentiated. This is consistent with reports that breast stem cells are CALLA-/MUC1- and express cytokeratin (CK) 19. In three-dimensional matrigel culture, SP (but not non-SP) cells produce branching structures similar to lobules. These structures comprise at least two cell populations expressing either CK14 (myoepithelial) or CK18 (luminal), suggesting that SP cells include a population with the potential to differentiate. Next, we analysed the relationship between steroid receptor expression, proliferation and CK19 expression. Results show that only 10–20% of breast epithelial cells contain receptors for estrogen and progesterone (ERa and PR), that these cells (70–80%) are in an intermediate/suprabasal position, are rarely proliferative and co-express CK19 providing evidence for ERa/PR expression by stem cells. These data are supported by the finding that SP cells are six times more likely to express steroid receptors than non-SP cells (60% versus 10%). Another population enriched for stem cells, the label retaining cells, express the putative stem cell markers Musashi-1 (Msi1) and p21CIP1, and are also ERa/PR-positive, although Msi1 and p21CIP1 are never co-expressed, suggesting that these molecules have separate functions in stem cell regulation. The data suggest that ERa/PR-positive human breast epithelial cells include a stem cell population and thus steroid receptor-positive breast cancers may arise from steroid receptor-positive stem cells present in the normal breast epithelium.

Highlights

  • The remarkable generation of scores of increasingly sophisticated mouse models of mammary cancer over the past two decades has provided tremendous insights into molecular derangements that can lead to cancer

  • We report that somatic mutations of p53 in mouse mammary epithelial cells lead to ERα-positive and ERαnegative tumors. p53 inactivation in pre-pubertal/pubertal mice, but not in adult mice, leads to the development of ERα-positive tumors, suggesting that developmental stages influence the availability of ERα-positive tumor origin cells

  • Genetic alterations commonly observed in human breast cancer including c-myc amplification and Her2/Neu/erbB2 activation were seen in these mouse tumors

Read more

Summary

Mouse models of human breast cancer: evolution or convolution?

Transgenic Oncogenesis Group, Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland, USA. The remarkable generation of scores of increasingly sophisticated mouse models of mammary cancer over the past two decades has provided tremendous insights into molecular derangements that can lead to cancer. The relationships of these models to human breast cancer, remain problematic. P53 inactivation in pre-pubertal/pubertal mice, but not in adult mice, leads to the development of ERα-positive tumors, suggesting that developmental stages influence the availability of ERα-positive tumor origin cells. These tumors have a high rate of metastasis that is independent of tumor latency. Since it is feasible to isolate ERα-positive epithelial cells from normal mammary glands and tumors, molecular mechanisms underlying ERα-positive and ERα-negative mammary carcinogenesis can be systematically addressed using this model

Mouse models for BRCA1-associated breast cancer
Genetic manipulation of the mammary gland by transplantation
The Mutant Mouse Regional Resource Center Program
11 Mammary pathology of the genetically engineered mouse
D Dugger
15 Role of animal models in oncology drug discovery
18 Clinical breast cancer and estrogen
19 Pregnancy levels of estrogen prevents breast cancer
21 The ErbB receptor tyrosine kinases and their roles in cancer
22 Predicting breast cancer behavior by microarray analysis
24 The comparative genetics and genomics of cancer: of mice and men
23 The molecular biology of mammary intraepithelial neoplasia outgrowths
28 Transgenic models are predictive: the herceptin and flavopiridol experience
31 Role of differentiation in carcinogenesis and cancer prevention
30 Genetically engineered mouse models of human breast cancer
34 Hormonal interactions during mammary gland development
35 Function of LEF1 in early mammary development
40 Imaging mouse models of breast cancer with positron emission tomography
42 Ultrasound imaging of tumor perfusion
D Medina
47 In situ to invasive carcinoma transition: escape or release
48 Regulation of human mammary stem cells
50 Stem cells in normal breast development and breast cancer
McKenzie
57 Genomic approaches to drug target discovery using mouse models
58 Target discovery in the postgenomic era
60 From gene expression patterns to antibody diagnostics
Findings
A Korman

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.